![](/images/graphics-bg.png)
Mycophenolate mofetil or cyclophosphamide in Indian patients with lupus nephritis : which is better ? a single-center experience
المؤلفون المشاركون
Gupta, Devika
Gupta, Pooja
Ali, Sufia
Mendonca, Satish
المصدر
Saudi Journal of Kidney Diseases and Transplantation
العدد
المجلد 28، العدد 5 (31 أكتوبر/تشرين الأول 2017)، ص ص. 1069-1077، 9ص.
الناشر
تاريخ النشر
2017-10-31
دولة النشر
السعودية
عدد الصفحات
9
التخصصات الرئيسية
الموضوعات
الملخص EN
Mycophenolate mofetil (MMF) is used extensively for the induction therapy of lupus nephritis (LN) and has even outpaced intravenous (i.v.) cyclophosphamide (CyP) as the initial choice of therapy.
There are no studies comparing the response of MMF with standard dose i.v.
CyP in Indian patients with LN.
We conducted a 24-week prospective, randomized, openlabel trial comparing oral MMF with monthly i.v.
CyP as induction therapy for active biopsy proven Class III and IV LN.
The primary end-point was response to treatment at 24 weeks, and the secondary end-points were complete remission, Systemic Lupus Erythematosus Disease Activity Index scores (SLEDAI) and adverse reactions.
Of the 40 patients, 17 were randomized to the MMF group and 23 to the i.v.
CyP group.
Complete remission was seen in nine (52.94%) patients in the MMF group and 11 (47.82 %) in the i.v.
CyP group.
Partial remission was seen in six (35.30 %) in the MMF group and nine (39.13%) in the i.v.
CyP group.
At six months, the cumulative probability of response was not statistically significant between the two groups (P = 1.000).
MMF is comparable to i.v.
CyP in the management of LN in Indian patients having an equal safety profile.
The dose of MMF required was lower than the conventional doses used in other studies suggesting genetic or environmental factors in the Indian population influencing the metabolism of MMF, which requires further evaluation.
The cost of MMF is a limiting factor in its use.
The use of i.v.
CyP is favorable as the monthly doses ensure compliance and is also cost-effective.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mendonca, Satish& Gupta, Devika& Ali, Sufia& Gupta, Pooja. 2017. Mycophenolate mofetil or cyclophosphamide in Indian patients with lupus nephritis : which is better ? a single-center experience. Saudi Journal of Kidney Diseases and Transplantation،Vol. 28, no. 5, pp.1069-1077.
https://search.emarefa.net/detail/BIM-776899
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mendonca, Satish…[et al.]. Mycophenolate mofetil or cyclophosphamide in Indian patients with lupus nephritis : which is better ? a single-center experience. Saudi Journal of Kidney Diseases and Transplantation Vol. 28, no. 5 (Sep. / Oct. 2017), pp.1069-1077.
https://search.emarefa.net/detail/BIM-776899
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mendonca, Satish& Gupta, Devika& Ali, Sufia& Gupta, Pooja. Mycophenolate mofetil or cyclophosphamide in Indian patients with lupus nephritis : which is better ? a single-center experience. Saudi Journal of Kidney Diseases and Transplantation. 2017. Vol. 28, no. 5, pp.1069-1077.
https://search.emarefa.net/detail/BIM-776899
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 1076-1077
رقم السجل
BIM-776899
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)